Work

Germline DDX41 mutant predisposition syndromes: Slow driver states to hematological malignancies

Year: 2023

Type: article

Abstract: Mrinal M Patnaik has received research funding from StemLine Pharmaceuticals, Kura Oncology, and Epigenetix. He has served on the advisory board for CTI pharmaceuticals. No original data contained in the manuscript.

Source: American Journal of Hematology

DOI: 10.1002/ajh.27091

Authors: Timothy M. Chlon, Mrinal M. Patnaik

Institutions: Cincinnati Children's Hospital Medical Center, Mayo Clinic

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4386726308

FWCI: 0.823

Cites: 22

Cited by: 4

Related to: 10